{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:51:32Z","timestamp":1787320292825,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273052"],"award-info":[{"award-number":["82273052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"R&D Program of Beijing Municipal Education Commission","award":["KZ202110025028"],"award-info":[{"award-number":["KZ202110025028"]}]},{"name":"the National High-Level Hospital Clinical Research Funding","award":["2024-NHLHCRF-PYI-06, 2024-NHLHCRF-YXHZ-MS-06"],"award-info":[{"award-number":["2024-NHLHCRF-PYI-06, 2024-NHLHCRF-YXHZ-MS-06"]}]},{"name":"Independent Research Project of China Academy of Chinese Medical Sciences","award":["No.YZ202117"],"award-info":[{"award-number":["No.YZ202117"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01529-4","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:10:06Z","timestamp":1744701006000},"page":"318-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bispecific antibody targeting CD155 mediates T-cell immunotherapy against human gynecological malignancies"],"prefix":"10.1007","volume":"43","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"3","key":"1529_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1529_CR2","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, Zhou Z, Yin P, Zhou M (2023) National and subnational trends in cancer burden in China, 2005\u201320: an analysis of national mortality surveillance data. Lancet Public Health 8(12):e943\u2013e955","journal-title":"Lancet Public Health"},{"issue":"12","key":"1529_CR3","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s43018-024-00860-8","volume":"5","author":"RJ Kishton","year":"2024","unstructured":"Kishton RJ, Restifo NP (2024) T cells lead the charge against solid tumors. Nat Cancer 5(12):1762\u20131764","journal-title":"Nat Cancer"},{"issue":"11","key":"1529_CR4","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh CH, Lee S, Kwak M, Kim BS, Chung Y (2023) CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp Mol Med 55(11):2287\u20132299","journal-title":"Exp Mol Med"},{"issue":"1","key":"1529_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41392-024-02118-2","volume":"10","author":"G Zhu","year":"2025","unstructured":"Zhu G, Tang Z, Chu T, Wang B, Chen S, Tao C, Cai J, Yang R, Qu W, Wang Y, Zhao Q, Huang R, Tian M, Fang Y, Gao J, Wu X, Zhou J, Liu W, Dai Z, Shi Y, Fan J (2025) Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells. Sig Transduct Target Ther 10(1):25","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"1529_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41420-025-02329-8","volume":"11","author":"M Passariello","year":"2025","unstructured":"Passariello M, Manna L, RapuanoLembo R, Yoshioka A, Inoue T, Kajiwara K, Hashimoto S, Nakamura K, De Lorenzo C (2025) Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics. Cell Death Discov 11(1):58","journal-title":"Cell Death Discov"},{"issue":"1","key":"1529_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s42003-024-06682-9","volume":"7","author":"C Liao","year":"2024","unstructured":"Liao C, Engelberts P, IoanFacsinay A, Klip JE, Schmidt T, Ruijtenbeek R, Danen EHJ (2024) CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing. Commun Biol 7(1):983","journal-title":"Commun Biol"},{"issue":"8","key":"1529_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1349-7006.2003.tb01499.x","volume":"94","author":"Y Takai","year":"2003","unstructured":"Takai Y, Irie K, Shimizu K, Sakisaka T, Ikeda W (2003) Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci 94(8):655\u2013667","journal-title":"Cancer Sci"},{"key":"1529_CR9","doi-asserted-by":"publisher","first-page":"111896","DOI":"10.1016\/j.intimp.2024.111896","volume":"131","author":"J Wu","year":"2024","unstructured":"Wu J, Liu Y, Dai X, Liu H, Zheng Y, Liu H (2024) CD155 as an emerging target in tumor immunotherapy. Int Immunopharmocal 131:111896","journal-title":"Int Immunopharmocal"},{"key":"1529_CR10","doi-asserted-by":"publisher","first-page":"216381","DOI":"10.1016\/j.canlet.2023.216381","volume":"573","author":"R Zhou","year":"2023","unstructured":"Zhou R, Chen S, Wu Q, Liu L, Wang Y, Mo Y, Zeng Z, Zu X, Xiong W, Wang F (2023) CD155 and its receptors in cancer immune escape and immunotherapy. Cancer Lett 573:216381","journal-title":"Cancer Lett"},{"issue":"1","key":"1529_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semcancer.2019.11.013","volume":"65","author":"JS O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell JS, Madore J, Li XY, Smyth MJ (2020) Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol 65(1):189\u2013196","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1529_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13046-021-02068-5","volume":"40","author":"B Wu","year":"2021","unstructured":"Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Zhao X, Yu Y, Zhang H, Xu F, Tian Y (2021) Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res 40(1):267","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"1529_CR13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/cas.14734","volume":"112","author":"T Murakami","year":"2021","unstructured":"Murakami T, Takasawa A, Takasawa K, Akimoto T, Aoyama T, Magara K, Saito Y, Ota M, Kyuno D, Yamamoto S, Hasegawa T, Saito T, Osanai M (2021) Aberrant expression of junctional adhesion molecule-A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor\/CD155. Cancer Sci 112(2):906\u2013917","journal-title":"Cancer Sci"},{"issue":"1","key":"1529_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-022-03480-x","volume":"20","author":"L Liu","year":"2022","unstructured":"Liu L, Wang A, Liu X, Han S, Sun Y, Zhang J, Guo L, Zhang Y (2022) Blocking TIGIT\/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer. J Transl Med 20(1):280","journal-title":"J Transl Med"},{"key":"1529_CR15","doi-asserted-by":"publisher","first-page":"655302","DOI":"10.3389\/fonc.2021.655302","volume":"11","author":"L Liu","year":"2021","unstructured":"Liu L, Wang Y, Geng C, Wang A, Han S, You X, Sun Y, Zhang J, Lu W, Zhang Y (2021) CD155 Promotes the Progression of Cervical Cancer Cells Through AKT\/mTOR and NF-\u03baB Pathways. Front Oncol 11:655302","journal-title":"Front Oncol"},{"issue":"17","key":"1529_CR16","doi-asserted-by":"publisher","first-page":"e2117065119","DOI":"10.1073\/pnas.2117065119","volume":"119","author":"D Ozmadenci","year":"2022","unstructured":"Ozmadenci D, Narayanan JSS, Andrew J, Ojalill M, Barrie AM, Jiang S, Iyer S, Chen X, Rose M, Estrada V, Molinolo A, Bertotto T, Mikulski Z, McHale MC, White RR, Connolly DC, Pachter JA, Kuchroo VK, Stupack DG, Schlaepfer DD (2022) Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis. Proc Natl Acad Sci 119(17):e2117065119","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1529_CR17","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1042\/BST20240386","volume":"52","author":"ER Webb","year":"2024","unstructured":"Webb ER, Black A, Barth ND, Symeonides SN, Brunton VG (2024) The integrin adhesome and control of anti-tumour immunity. Biochem Soc Trans 52(6):2455\u20132468","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"1529_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41467-024-55430-4","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhang B, Zhang M, Li W, Li H, Jiao Y, Yang Q, Wang S, Liu Y, Song A, Feng H, Sun J, Kwok RTK, Lam JWY, Tang B, Sun Z (2025) Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy. Nat Commun 16(1):44","journal-title":"Nat Commun"},{"issue":"6","key":"1529_CR19","doi-asserted-by":"publisher","first-page":"e13249","DOI":"10.1111\/cpr.13249","volume":"55","author":"Z Yu","year":"2022","unstructured":"Yu Z, Zhang J, Zhang Q, Wei S, Shi R, Zhao R, An L, Grose R, Feng D, Wang H (2022) Single-cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer. Cell Prolif 55(6):e13249","journal-title":"Cell Prolif"},{"issue":"20","key":"1529_CR20","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.3390\/cancers13205246","volume":"13","author":"P De","year":"2021","unstructured":"De P, Aske J, Dey N (2021) Cancer-associated fbroblast functions as a road-block in cancer therapy. Cancers (Basel) 13(20):5246","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1529_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00262-024-03766-7","volume":"73","author":"K Seel","year":"2024","unstructured":"Seel K, Schirrmann RL, Stowitschek D, Ioseliani T, Roiter L, Knierim A, Andre MC (2024) Blockade of the TIGIT-CD155\/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia. Cancer Immunol Immunother 73(9):180","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1529_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s10637-023-01367-2","volume":"41","author":"L Ma","year":"2023","unstructured":"Ma L, Ma J, Sun X, Liu H (2023) Bispecific anti-CD3\u00d7anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies. Invest New Drugs 41(3):522\u2013531","journal-title":"Invest New Drugs"},{"issue":"21","key":"1529_CR23","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.7150\/jca.29937","volume":"10","author":"W Ma","year":"2019","unstructured":"Ma W, Ma J, Lei T, Zhao M, Zhang M (2019) Targeting immunotherapy for bladder cancer by using anti-CD3 \u00d7 anti-CD155 bispecific antibody. J Cancer 10(21):5153\u20135161","journal-title":"J Cancer"},{"issue":"5","key":"1529_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10637-018-0683-9","volume":"37","author":"H Zhao","year":"2019","unstructured":"Zhao H, Ma J, Lei T, Ma W, Zhang M (2019) The bispecific anti-CD3 \u00d7 anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer. Invest New Drugs 37(5):810\u2013817","journal-title":"Invest New Drugs"},{"issue":"1","key":"1529_CR25","first-page":"1","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Yang Z, Du G, Cao L, Tan B (2021) CD155-prognositic and immunotherapeutic implications based on multiple analyses of databased across 33 human cancers. Technol Cancer Res Treat 20(1):1\u201312","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"1529_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.immuni.2020.09.010","volume":"53","author":"M Braun","year":"2020","unstructured":"Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Guzman MLG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, H\u00f6lzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, M\u00f6ller A, Johnston RJ, Martinet L, Smyth MJ, Bald T (2020) CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T Cells. Immunity 53(4):805\u2013823","journal-title":"Immunity"},{"issue":"1","key":"1529_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41423-018-0168-y","volume":"16","author":"P Ku\u010danBrli\u0107","year":"2019","unstructured":"Ku\u010danBrli\u0107 P, Rovi\u0161 TL, Cinamon G, Tsukerman P, Mandelboim O, Jonji\u0107 S (2019) Targeting PVR(CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 16(1):40\u201352","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"1529_CR28","doi-asserted-by":"publisher","first-page":"e0152982","DOI":"10.1371\/journal.pone.0152982","volume":"11","author":"A Iguchi-Manaka","year":"2016","unstructured":"Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, Sato T, Yoshikawa H, Hara H, Shibuya A, Shibuya K (2016) Increased soluble CD155 in serum of cancer patients. PLoS ONE 11(4):e0152982","journal-title":"PLoS ONE"},{"issue":"1","key":"1529_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2017.09.001","volume":"242","author":"JR Bowers","year":"2017","unstructured":"Bowers JR, Readler JM, Sharma P, Excoffon KJDA (2017) Poliovirus Receptor: More than a simple viral receptor. Virus Res 242(1):1\u20136","journal-title":"Virus Res"},{"key":"1529_CR30","doi-asserted-by":"publisher","first-page":"116441","DOI":"10.1016\/j.bcp.2024.116441","volume":"227","author":"D Liu","year":"2024","unstructured":"Liu D, Hu X, Chen Z, Wei W, Wu Y (2024) Key links in the physiological regulation of the immune system and disease induction: T cell receptor -CD3 complex. Biochem Pharmacol 227:116441","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1529_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13046-022-02474-3","volume":"41","author":"M Passariello","year":"2022","unstructured":"Passariello M, Yoshioka A, Takahashi K, Hashimoto SI, Inoue T, Nakamura K, De Lorenzo C (2022) Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. J Exp Clin Cancer Res 41(1):269","journal-title":"J Exp Clin Cancer Res"},{"key":"1529_CR32","doi-asserted-by":"publisher","first-page":"883010","DOI":"10.3389\/fimmu.2022.883010","volume":"13","author":"C Cassioli","year":"2022","unstructured":"Cassioli C, Baldari CT (2022) The Expanding Arsenal of Cytotoxic T Cells. Front Immunol 13:883010","journal-title":"Front Immunol"},{"issue":"2","key":"1529_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41379-021-00882-y","volume":"35","author":"AM Mills","year":"2022","unstructured":"Mills AM, Bullock TN, Ring KL (2022) Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. Mod Pathol 35(2):142\u2013151","journal-title":"Mod Pathol"},{"issue":"16","key":"1529_CR34","doi-asserted-by":"publisher","first-page":"12958","DOI":"10.3390\/ijms241612958","volume":"24","author":"R Paolini","year":"2023","unstructured":"Paolini R, Molfetta R (2023) CD155 and its receptors as targets for cancer therapy. Int J Mol Sci 24(16):12958","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1529_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/0008-5472.CAN-24-1509","volume":"85","author":"X Wang","year":"2025","unstructured":"Wang X, Wang H, Lu Z, Liu X, Chai W, Wang W, Feng J, Yang S, Yang W, Cheng H, Chen C, Zhang S, Sun N, Liu Q, Li Q, Song W, Jin F, Zeng Q, Wang S, Su Y, Wang H, Ni X, Gui J (2025) Spatial and single-cell analyses reveal heterogeneity of DNAM-1 receptor\u2013ligand interactions that instructs intratumoral \u03b3\u03b4 T-cell activity. Cancer Res 85(2):277\u2013298","journal-title":"Cancer Res"},{"issue":"20","key":"1529_CR36","doi-asserted-by":"publisher","first-page":"29480","DOI":"10.18632\/oncotarget.8784","volume":"7","author":"J Ma","year":"2016","unstructured":"Ma J, Ma P, Zhao C, Xue X, Han H, Liu C, Tao H, Xiu W, Cai J, Zhang M (2016) B7\u2013H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget 7(20):29480\u201329491","journal-title":"Oncotarget"},{"issue":"1","key":"1529_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10147-024-02640-x","volume":"30","author":"T Nagano","year":"2025","unstructured":"Nagano T, Takada K, Hashinokuchi A, Matsudo K, Kinoshita F, Akamine T, Kohno M, Shimokawa M, Takenaka T, Oda Y, Yoshizumi T (2025) Clinical significance of CD155 expression in surgically resected lung squamous cell carcinoma. Int J Clin Oncol 30(1):62\u201371","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"1529_CR38","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41375-024-02419-z","volume":"38","author":"L Martinez-Verno","year":"2024","unstructured":"Martinez-Verno L, Veselinova Y, Llinas-Arias P, Garcia-Prieto CA, Noguera-Castells A, Pato ML, Bueno-Costa A, Campillo-Marcos I, Villanueva L, Oliver-Caldes A, Cardus O, Salsench SV, Garcia-Ortiz A, Valeri A, Rojas EA, Barrena N, Gutierrez NC, Prosper F, Agirre X, de Larrea CF, Martinez-Lopez J, Ferrer G, Esteller M (2024) PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma. Leukemia 38(12):2722\u20132726","journal-title":"Leukemia"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01529-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01529-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01529-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:41:15Z","timestamp":1746178875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01529-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01529-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involved in studies involving human participants were performed in accordance with the ethics standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethics standards. This article does not describe any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}